Tao Wu, H. Cao, Jing Li, D. Mao, Cun-bang Wang, H. Bai, Ommega Internationals
{"title":"双费城染色体阳性B型急性淋巴母细胞白血病","authors":"Tao Wu, H. Cao, Jing Li, D. Mao, Cun-bang Wang, H. Bai, Ommega Internationals","doi":"10.15436/2381-1404.18.1900","DOIUrl":null,"url":null,"abstract":"Philadelphia (Ph) chromosome is the derivative chromosome 22 that results from reciprocal translocation t(9;22) (q34;q11). It has been found in about 95% of chronic myeloid leukemia (CML), less often presented in acute lymphocytic leukemia (ALL, about 25% in adult and 2 4% in pediatrics) and occasionally observed in acute myelogenous leukemia (AML) [1]. While double Ph chromosomes can be reported in some cases of CML during blastcrisis, it is rarely reported in ALL. We present a rare case of a lady with a diagnosis of double Ph-positive B-ALL who achieved a continuous complete response after treatment with a combination of conventional chemotherapy and tyrosine kinase inhibitor (TKI) as follows.","PeriodicalId":91287,"journal":{"name":"International journal of hematology & therapy","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Double Philadelphia Chromosome-Positive B Acute Lymphoblastic Leukemia\",\"authors\":\"Tao Wu, H. Cao, Jing Li, D. Mao, Cun-bang Wang, H. Bai, Ommega Internationals\",\"doi\":\"10.15436/2381-1404.18.1900\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Philadelphia (Ph) chromosome is the derivative chromosome 22 that results from reciprocal translocation t(9;22) (q34;q11). It has been found in about 95% of chronic myeloid leukemia (CML), less often presented in acute lymphocytic leukemia (ALL, about 25% in adult and 2 4% in pediatrics) and occasionally observed in acute myelogenous leukemia (AML) [1]. While double Ph chromosomes can be reported in some cases of CML during blastcrisis, it is rarely reported in ALL. We present a rare case of a lady with a diagnosis of double Ph-positive B-ALL who achieved a continuous complete response after treatment with a combination of conventional chemotherapy and tyrosine kinase inhibitor (TKI) as follows.\",\"PeriodicalId\":91287,\"journal\":{\"name\":\"International journal of hematology & therapy\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-07-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International journal of hematology & therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15436/2381-1404.18.1900\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of hematology & therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15436/2381-1404.18.1900","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Double Philadelphia Chromosome-Positive B Acute Lymphoblastic Leukemia
Philadelphia (Ph) chromosome is the derivative chromosome 22 that results from reciprocal translocation t(9;22) (q34;q11). It has been found in about 95% of chronic myeloid leukemia (CML), less often presented in acute lymphocytic leukemia (ALL, about 25% in adult and 2 4% in pediatrics) and occasionally observed in acute myelogenous leukemia (AML) [1]. While double Ph chromosomes can be reported in some cases of CML during blastcrisis, it is rarely reported in ALL. We present a rare case of a lady with a diagnosis of double Ph-positive B-ALL who achieved a continuous complete response after treatment with a combination of conventional chemotherapy and tyrosine kinase inhibitor (TKI) as follows.